Aiforia enters into an agreement with PathAI
Summary
- Aiforia has signed a commercial agreement with PathAI, part of the Roche Group, to distribute its AI solutions through PathAI's AISight image management system, expanding its US distribution network.
- The partnership aligns with Aiforia's strategy to integrate AI models into pathologists' workflows via open APIs, leveraging PathAI's established platform and simplifying customer adoption through unified contracts and support.
- The collaboration enhances Aiforia's US market position, although large-scale commercialization is limited by the lack of FDA approval, with growth potential through the LDT route.
- The key challenge for Aiforia is converting partnerships into revenue growth, particularly in the US market, following a recent period of stagnation.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 10/09/2026 at 07:10 am EEST
Aiforia announced on Thursday that it has signed a commercial agreement with PathAI, a member of the Roche Group. Through this collaboration, Aiforia's AI solutions will be available through the marketplace of PathAI's AISight image management system (IMS). The partnership expands the distribution network of Aiforia's software, particularly in the US. We expect that the expansion of distribution will bring gradual growth over time, and the news thus partly supports our growth estimates
Strong partner supports distribution and platform strategy
PathAI, acquired by pharmaceutical giant Roche earlier this year, is a major player in the digital pathology field, and the broad installed base of its AISight platform offers Aiforia a new and potential distribution channel. Aiforia's strategy is to integrate via open APIs into the image management systems (IMS) used by pathologists to make the AI models part of the laboratories' seamless workflow. The agreement with PathAI follows this platform strategy and is a continuation of previous similar partnerships (e.g. Siemens Healthineers, and Proscia). From the customer's perspective, we believe it is advantageous that PathAI is responsible for contracts, invoicing, and support within a unified ecosystem, which can lower the threshold to take Aiforia's algorithms into use. For Aiforia, the model is extremely capital-light.
Opening up the US market is a long game
The company highlighted in its release that the cooperation improves Aiforia's position, particularly in the US market, where PathAI has a strong presence. Among current partners, Proscia also holds a strong position in the US, and the new agreement thus further strengthens Aiforia's market coverage. Aiforia's competitive advantage in Europe has relied on a broad portfolio of CE-IVD-cleared models, but the company currently lacks FDA approval in the US, which limits large-scale commercialization. The PathAI collaboration can support Aiforia’s sales in the US through the so-called LDT (Laboratory Developed Test) route, but we believe that a large-scale breakthrough still requires FDA approvals. The key question for the coming years is how the company succeeds in converting its partnerships into revenue growth after the recent lull.